Pilar Acedo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9486798/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Young GI angle: What being a myUEG young GI associate can offer you—Check it out!. United European Gastroenterology Journal, 2022, 10, 134-135.	1.6	4
2	The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. Journal of Clinical Medicine, 2021, 10, 566.	1.0	21
3	Dual mitochondrial targeting as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, S71-S72.	0.5	0
4	Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum. Frontiers in Oncology, 2021, 11, 699401.	1.3	9
5	Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy. ACS Applied Materials & Interfaces, 2021, 13, 55790-55805.	4.0	8
6	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	2.9	37
7	Young GI Societies in Europe: 2019 update. United European Gastroenterology Journal, 2020, 8, 227-232.	1.6	10
8	How to start a Young GI Section in your country: A cookbook. United European Gastroenterology Journal, 2020, 8, 355-358.	1.6	5
9	Alkynyl N-BODIPYs as Reactive Intermediates for the Development of Dyes for Biophotonics. Chemistry Proceedings, 2020, 3, .	0.1	Ο
10	Young GI angle: A young point of view on translational medicine. United European Gastroenterology Journal, 2019, 7, 864-865.	1.6	1
11	Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Cancers, 2019, 11, 1372.	1.7	29
12	Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. Cell Death Discovery, 2019, 5, 77.	2.0	24
13	UEG Young Talent Group: What do we do?. United European Gastroenterology Journal, 2019, 7, 166-168.	1.6	5
14	Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in <i>TP53</i> mutant pancreatic tumors. Future Science OA, 2019, 5, FSO366.	0.9	16
15	Multimodal use of the porphyrin TMPyP: From cancer therapy to antimicrobial applications. Journal of Porphyrins and Phthalocyanines, 2019, 23, 11-27.	0.4	43
16	Combination light-based therapies to treat pancreatic cancer: a proof of concept. , 2019, , .		0
17	Verteporfin Photodynamic therapy with 5 aza-deoxy-cytidine for neo-adjuvant treatment of primary breast cancer: Results of pre-clinical investigations. , 2019, , .		0
18	Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells. Cell Division, 2018, 13, 10.	1.1	15

Pilar Acedo

#	Article	IF	CITATIONS
19	Improved selectivity and cytotoxic effects of irinotecan via liposomal delivery: A comparative study on Hs68 and HeLa cells. European Journal of Pharmaceutical Sciences, 2017, 109, 65-77.	1.9	18
20	Mutant p53 talks to proteasomes—is there a feedback loop between Nrf2 and mutant p53?. Translational Cancer Research, 2016, 5, 733-737.	0.4	0
21	Silica-based nanostructured materials for biomedical applications. , 2015, , 429-448.		3
22	p53 family members – important messengers in cell death signaling in photodynamic therapy of cancer?. Photochemical and Photobiological Sciences, 2015, 14, 1390-1396.	1.6	26
23	Poly(<i>D</i> , <i>L</i> -lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and photototoxicity by surface PEG coating. Nanotechnology, 2015, 26, 365104.	1.3	24
24	JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death and Disease, 2014, 5, e1484-e1484.	2.7	33
25	Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death and Disease, 2014, 5, e1122-e1122.	2.7	117
26	Efficient and safe internalization of magnetic iron oxide nanoparticles: Two fundamental requirements for biomedical applications. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 733-743.	1.7	101
27	Efficient induction of apoptosis in HeLa cells by a novel cationic porphycene photosensitizer. European Journal of Medicinal Chemistry, 2013, 63, 401-414.	2.6	23
28	Tricationic porphycene derivative Py3MeO–TBPo mediated photodynamic effects on tumour HeLa cells. Photodiagnosis and Photodynamic Therapy, 2011, 8, 187.	1.3	0
29	Cell death causes relocalization of photosensitizing fluorescent probes. Acta Histochemica, 2011, 113, 363-368.	0.9	24
30	Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. Biomaterials, 2011, 32, 2938-2952.	5.7	170
31	A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers. Photochemical and Photobiological Sciences, 2010, 9, 295-297.	1.6	33
32	Mitotic catastrophe induced in HeLa cells by photodynamic treatment with Zn(II)-phthalocyanine. International Journal of Oncology, 1992, 32, 1189-1196.	1.4	35